Physiomics PLC - oncology consultant based in Oxford - Says its partner study has recruited its first patient. Says the study, which received formal Health Research Authority ethics approval in December 2020, started recruiting this month, has been commissioned to gather data for the further development of Physiomics' personalised oncology dosing tool.
Current stock price: 6.73 pence
Year-to-date change: down 5.9%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Physiomics (PYC)